Biomedical Engineering Reference
In-Depth Information
References
1. Black LE, Bendele AM, Bendele RA, Zack PM,
Hamilton M (1999) Regulatory decision strat-
egy for entry of a novel biological therapeutic
with a clinically unmonitorable toxicity into
clinical trials: pre-IND meetings and a case
example. Toxicol Pathol 27(1):22-26
2. Food and Drug Administration Website.
Drugs @FDA: (
http://www.accessdata.fda.
3. European Medicines Agency Website. Human
medicines: (
http://www.ema.europa.eu/ema/
system in patients with persistent macular
edema. Arch Ophthalmol 125(3):309-317
14. Demill DL, Wirostko BM, Nelson LA, Stewart
JA, Stewart WC (2013) Average versus highest
intraocular pressure analyses in glaucoma clini-
cal trials. Ophthalmic Res 49(1):49-51
15. Miglior S, Bertuzzi F (2013) Relationship
between intraocular pressure and glaucoma
onset and progression. Curr Opin Pharmacol
13(1):32-35
16. European Medicines Agency (2012) Docu-
ment EMA/450332/2012. EU Regulatory
Workshop—Ophthalmology—Summary and
Report: Clinical Development, Scientific
Advice and Paediatric Investigation Plans
17. McLeod LD, Coon CD, Martin SA, Fehnel SE,
Hays RD (2011) Interpreting patient-reported
outcome results: US FDA guidance and
emerging methods. Expert Rev Pharmacoecon
Outcomes Res 11(2):163-169
18. Vandenbroeck S, De Geest S, Zeyen T, Stal-
mans I, Dobbels F (2011) Patient-reported
outcomes (PRO's) in glaucoma: a systematic
review. Eye (Lond) 25(5):555-577
19. Food and Drug Administration Website. New
drug application. (
http://www.fda.gov/
20. International Conference on Harmonisation
Website. Common technical document
21. Food and Drug Administration Website.
Approval process (
http://www.fda.gov/Drugs/
22. Food and Drug Administration Website.
Advisory committees (
http://www.fda.gov/
23. Food and Drug Administration Website.
Review process overview (
http://www.fda.
24. Congressional Research Service (2001) CRS
report for congress. The U.S. drug approval
process: a primer
25. Food and Drug Administration Website. Fast
Track, Accelerated Approval and Priority
Review (
http://www.fda.gov/ForConsumers/
26. Marchand HC, Ros BJ, Fine AM, Kremzner
ME (2012) The U.S. Food and drug
pages/regulation/landing/
human_medicines_regulatory.jsp&mid
¼
¼
WC0b01ac058001ff89)
4. Kohler M (2011) Regulatory pathways in the
European Union. MAbs 3(3):241-242
5. International Conference on Harmonisation
Website (
http://www.ich.org/
)
6. Food and Drug Administration Website. Inves-
tigational new drug application (
http://www.
7. European Medicines Agency (2009) Docu-
ment CPMP/ICH/286/95: Note for guid-
ance on non-clinical safety studies for the
conduct of human clinical trials and marketing
authorization for pharmaceuticals
8. Investigational Medicinal Product Dossier
Website (
http://www.impd.eu/
)
9. International Conference on Harmonisation
Website. Safety guidelines (
http://www.ich.
10. Food and Drug Administration Website. Drug
Development and Review Definitions (
http://
11. European Medicines Agency (1998) Docu-
ment CPMP/ICH/291/95: Note for guid-
ance on general consideration for clinical trials
12. Food and Drug Administration, Center for
Drug Evaluation and Research (2009) Guid-
ance for industry: End of phase 2A meetings.
Available at:
http://www.fda.gov/downloads/
Accessed on 18 January 2013
13. Kuppermann BD, Blumenkranz MS, Haller JA
et al (2007) Randomized controlled study of
an intravitreous dexamethasone drug delivery
